trending Market Intelligence /marketintelligence/en/news-insights/trending/uckfsum697-fn5u-rx9o8a2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Indivior's Perseris gets US FDA approval as schizophrenia treatment

Blog

M&A rebound sparks optimism for near-term deal activity

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud


Indivior's Perseris gets US FDA approval as schizophrenia treatment

Indivior PLC said the U.S. Food and Drug Administration approved Perseris, a once-monthly injectable that contains risperidone, for adults with schizophrenia.

Risperidone is an established treatment for schizophrenia, a serious mental disorder that affects a patient's thoughts, emotions and behavior.

Perseris provides patients sustained levels of risperidone over one month via an extended-release delivery system.

The Richmond, Va.-based drugmaker's application was backed by late-stage trial data demonstrating Perseris' efficacy, even without a loading dose or any supplemental oral risperidone.